Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.57 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 9/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | CCR4 | P51679 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP10 | P09238 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | MMP14 | P50281 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1932381 | 0.83 | MAPT (0.54) | GAAKMT2ARAB9AMAPTMEN1 | |
| SCHEMBL13503715 | 0.83 | RAB9A (0.62) | GAAKMT2ARAB9ACSNK2A1PLK3 | |
| SCHEMBL10464778 | 0.83 | GAA (0.57) | GAAKMT2ARAB9ACSNK2A1PLK3 | |
| Hydrochloric Acid SCHEMBL3217563 | 0.82 | MAPT (0.52) | GAAKMT2ARAB9AMAPTMEN1 | |
| SCHEMBL13181102 | 0.80 | ADRB2 (0.59) | GAAKMT2ARAB9ACSNK2A1PLK3 | |
| SCHEMBL9385942 | 0.80 | CSNK2A1 (0.58) | GAAKMT2ARAB9ACSNK2A1PLK3 | |
| SCHEMBL10098814 | 0.79 | RAB9A (0.57) | GAAKMT2ARAB9ACSNK2A1PLK3 | |
| SCHEMBL5488921 | 0.79 | RAB9A (0.57) | GAAKMT2ARAB9ACSNK2A1PLK3 | |
| SCHEMBL13153208 | 0.79 | CCR4 (0.64) | GAAKMT2ARAB9ACSNK2A1PLK3 | |
| SCHEMBL18835237 | 0.79 | ALOX5 (0.59) | GAAKMT2ARAB9ACSNK2A1PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2172450-B9 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-08 | — | — | EP | disclosed |
| CN-101784520-B | Novel malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORP | 2014-07-02 | — | — | CN | disclosed |
| US-8691850-B2 | Substituted phenylaminothiazoles and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-08 | — | — | US | disclosed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8106209-B2 | Substituted aminothiazole prodrugs of compounds with anti-HCV activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| CN-101784520-A | Novel malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORP | 2010-07-21 | — | — | CN | disclosed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20100048641-A1 | Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases | BAYER HEALTHCARE AG LAW AND PATENTS,PATENTS AND LICENSING (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20090304605-A1 | Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048641-A1 | Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases | ADORA1, ADORA2B, ADORA2A | GAA 901/4885KMT2A 2140/4885RAB9A 2327/4885 |
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | PAH, TNNT2, VHL | GAA 1185/4885KMT2A 1756/4885RAB9A 4441/4885 |
| US-20090304605-A1 | Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity | BCAT1, CCNT1, EIF2AK2 | GAA 1018/4885KMT2A 2806/4885RAB9A 948/4885 |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | EIF2AK2, BCAT1, IL4I1 | GAA 1919/4885KMT2A 2793/4885RAB9A 1099/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | GAA 272/4885KMT2A 1948/4885RAB9A 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.